Celltrion, Inc.
Biopharmaceutical firm developing biosimilars for autoimmune diseases and oncology.
068270 | KO
Overview
Corporate Details
- ISIN(s):
- KR7068270008
- LEI:
- Country:
- South Korea
- Address:
- 인천광역시 연수구 아카데미로 23, 인천광역시
- Website:
- https://www.celltrion.com/
- Sector:
- Manufacturing
Description
Celltrion, Inc. is a biopharmaceutical company that provides integrated solutions across the entire value chain, from research and development to clinical trials, regulatory affairs, and large-scale manufacturing. The company specializes in developing and producing innovative therapeutics, including biosimilars and novel biopharmaceuticals. Its portfolio primarily targets autoimmune diseases and oncology. Celltrion is recognized for launching the world's first monoclonal antibody biosimilar. A key product is ZYMFENTRA® (infliximab-dyyb), a subcutaneous formulation for the maintenance treatment of moderately-to-severely active Crohn's disease and ulcerative colitis. The company also develops and manufactures chemical pharmaceuticals.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-02-22 00:00 |
영업(잠정)실적(공정공시)
|
Korean | 13.5 KB | ||
| 2021-02-22 00:00 |
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 15.2 KB | ||
| 2021-02-22 00:00 |
매출액또는손익구조30%(대규모법인은15%)이상변경
|
Korean | 12.9 KB | ||
| 2021-02-22 00:00 |
주주총회소집결의
|
Korean | 14.9 KB | ||
| 2021-02-22 00:00 |
단일판매ㆍ공급계약체결
|
Korean | 8.1 KB | ||
| 2021-02-22 00:00 |
특수관계인과의내부거래
|
Korean | 6.6 KB | ||
| 2021-02-22 00:00 |
특수관계인에대한자산양도
|
Korean | 6.0 KB | ||
| 2021-02-18 00:00 |
투자판단관련주요경영사항(CT-P41(프롤리아 바이오시밀러) 임상 3상 시험계획 유럽 우크라이나 신청)
|
Korean | 11.7 KB | ||
| 2021-02-17 00:00 |
투자판단관련주요경영사항(CT-P41(프롤리아 바이오시밀러) 임상 3상 시험계획 미국 FDA 승인)
|
Korean | 11.4 KB | ||
| 2021-02-17 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 529.2 KB | ||
| 2021-02-17 00:00 |
투자판단관련주요경영사항(CT-P42(아일리아 바이오시밀러) 임상 3상 시험계획 미국 FDA 신청)
|
Korean | 10.9 KB | ||
| 2021-02-16 00:00 |
투자판단관련주요경영사항(CT-P41(프롤리아 바이오시밀러) 임상 3상 시험계획 국내 식약처 신청)
|
Korean | 11.3 KB | ||
| 2021-02-16 00:00 |
투자판단관련주요경영사항(CT-P42(아일리아 바이오시밀러) 임상 3상 시험계획 국내 식약처 신청)
|
Korean | 11.1 KB | ||
| 2021-02-15 00:00 |
투자판단관련주요경영사항(유플라이마(프로젝트명: CT-P17, Humira biosimilar), 유럽연합집행위원회(EC) 최종판매허가 획득)
|
Korean | 8.3 KB | ||
| 2021-02-05 00:00 |
투자판단관련주요경영사항(코로나19 바이러스(SARS-CoV-2) 감염환자 치료제, 렉키로나주(프로젝트명: CT-P59) 국내 조건부허가 획득)
|
Korean | 10.3 KB |
Automate Your Workflow. Get a real-time feed of all Celltrion, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Celltrion, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Celltrion, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
